PMID- 36143358
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230308
IS  - 2075-1729 (Print)
IS  - 2075-1729 (Electronic)
IS  - 2075-1729 (Linking)
VI  - 12
IP  - 9
DP  - 2022 Aug 26
TI  - Endothelial Dysfunction in Patients with Advanced Heart Failure Treated with 
      Levosimendan Periodic Infusion Compared with Optimal Medical Therapy: A Pilot 
      Study.
LID - 10.3390/life12091322 [doi]
LID - 1322
AB  - Endothelial dysfunction (ED) is frequently found in patients with heart failure 
      (HF). Among several pharmacological agents reported to improve endothelial 
      function, levosimendan seems to be a promising one, even though, to date, only 
      two previously published studies have evaluated its effects on ED in these 
      patients. The aim of our pilot study was to further investigate the role of 
      periodic levosimendan infusion on endothelial function in patients affected by 
      advanced HF. In this cross-sectional study, three different groups were enrolled: 
      20 patients with advanced HF treated with periodic levosimendan (LEVO), 20 
      patients with HF on optimal medical therapy (OMT), and 20 healthy subjects 
      (control group). ED was evaluated through flow-mediated dilation (FMD) at the 
      level of the brachial artery. The three groups presented similar ages with 
      significant differences in gender distribution, systolic blood pressure, and 
      chronic kidney disease (eGFR < 30 mL/min). In HF patients, ischaemic aetiology 
      was more prevalent in the LEVO group than in the OMT group (60 vs. 40%, p < 
      0.001). The New York Heart Association (NYHA) functional class was worse in the 
      LEVO group, as well as in NT-proBNP (5636.7 +/- 6164.6 ng/dL and 1243.7 +/- 1487.2 
      ng/dL, in the LEVO and OMT groups, respectively, p = 0.005). The FMD was 
      significantly higher in the healthy control group compared to that of the OMT 
      group (15.7 +/- 6.4 vs. 9.1 +/- 6.0%, p = 0.007) while it showed an intermediate 
      value in LEVO patients (12.4 +/- 7.1%) (ANOVA p = 0.010). In conclusion, 
      levosimendan therapy seems to ameliorate endothelial dysfunction related to heart 
      failure. Longitudinal studies in patients on periodic therapy are needed in order 
      to confirm the long-term effects of levosimendan on ED.
FAU - Maloberti, Alessandro
AU  - Maloberti A
AUID- ORCID: 0000-0002-2612-6264
AD  - Cardiology 4, Cardio Center, ASST GOM Niguarda, Piazza Ospedale Maggiore 3, 20159 
      Milan, Italy.
AD  - School of Medicine and Surgery, University of Milano-Bicocca, 20126 Milan, Italy.
FAU - Sun, Jinwei
AU  - Sun J
AD  - School of Medicine and Surgery, University of Milano-Bicocca, 20126 Milan, Italy.
FAU - Zannoni, Jessica
AU  - Zannoni J
AD  - School of Medicine and Surgery, University of Milano-Bicocca, 20126 Milan, Italy.
FAU - Occhi, Lucia
AU  - Occhi L
AUID- ORCID: 0000-0001-6722-4584
AD  - Cardiology 4, Cardio Center, ASST GOM Niguarda, Piazza Ospedale Maggiore 3, 20159 
      Milan, Italy.
FAU - Bassi, Ilaria
AU  - Bassi I
AD  - Cardiology 4, Cardio Center, ASST GOM Niguarda, Piazza Ospedale Maggiore 3, 20159 
      Milan, Italy.
FAU - Fabbri, Saverio
AU  - Fabbri S
AD  - School of Medicine and Surgery, University of Milano-Bicocca, 20126 Milan, Italy.
FAU - Colombo, Valentina
AU  - Colombo V
AD  - School of Medicine and Surgery, University of Milano-Bicocca, 20126 Milan, Italy.
FAU - Gualini, Elena
AU  - Gualini E
AD  - School of Medicine and Surgery, University of Milano-Bicocca, 20126 Milan, Italy.
FAU - Algeri, Michela
AU  - Algeri M
AD  - Cardiology 4, Cardio Center, ASST GOM Niguarda, Piazza Ospedale Maggiore 3, 20159 
      Milan, Italy.
FAU - Varrenti, Marisa
AU  - Varrenti M
AUID- ORCID: 0000-0003-4375-5991
AD  - Cardiology 2, Cardio Center, ASST GOM Niguarda, 20126 Milan, Italy.
FAU - Masciocco, Gabriella
AU  - Masciocco G
AD  - Cardiology 2, Cardio Center, ASST GOM Niguarda, 20126 Milan, Italy.
FAU - Perna, Enrico
AU  - Perna E
AD  - Cardiology 2, Cardio Center, ASST GOM Niguarda, 20126 Milan, Italy.
FAU - Oliva, Fabrizio
AU  - Oliva F
AD  - Cardiology 1, Cardio Center, ASST GOM Niguarda, 20126 Milan, Italy.
FAU - Cipriani, Manlio
AU  - Cipriani M
AD  - Cardiology 2, Cardio Center, ASST GOM Niguarda, 20126 Milan, Italy.
FAU - Frigerio, Maria
AU  - Frigerio M
AD  - Cardiology 2, Cardio Center, ASST GOM Niguarda, 20126 Milan, Italy.
FAU - Giannattasio, Cristina
AU  - Giannattasio C
AD  - Cardiology 4, Cardio Center, ASST GOM Niguarda, Piazza Ospedale Maggiore 3, 20159 
      Milan, Italy.
AD  - School of Medicine and Surgery, University of Milano-Bicocca, 20126 Milan, Italy.
LA  - eng
GR  - 1/CX/CSRD VA/United States
GR  - Department of Excellence project PREMIA (PREcision MedIcine Approach: bringing 
      biomarker research to clinic)/Italian Ministry of University and Research (MIUR)/
PT  - Journal Article
DEP - 20220826
PL  - Switzerland
TA  - Life (Basel)
JT  - Life (Basel, Switzerland)
JID - 101580444
PMC - PMC9501966
OTO - NOTNLM
OT  - endothelial dysfunction
OT  - flow-mediated vasodilation
OT  - heart failure
OT  - levosimendan
COIS- The authors declare no conflict of interest.
EDAT- 2022/09/24 06:00
MHDA- 2022/09/24 06:01
PMCR- 2022/08/26
CRDT- 2022/09/23 01:29
PHST- 2022/07/27 00:00 [received]
PHST- 2022/08/21 00:00 [revised]
PHST- 2022/08/23 00:00 [accepted]
PHST- 2022/09/23 01:29 [entrez]
PHST- 2022/09/24 06:00 [pubmed]
PHST- 2022/09/24 06:01 [medline]
PHST- 2022/08/26 00:00 [pmc-release]
AID - life12091322 [pii]
AID - life-12-01322 [pii]
AID - 10.3390/life12091322 [doi]
PST - epublish
SO  - Life (Basel). 2022 Aug 26;12(9):1322. doi: 10.3390/life12091322.